Quick identification of target antigens by tissue flow cytometry for <scp>CAR‐T</scp> therapy in B‐cell malignancies

Yu, Xudong; Li, Pan; Wang, Anne Aofan; Feng, Heyuan; Yin, Zhichao; Li, Yafeng; Kang, Jian; Zheng, Xichang; Yang, Wenhong; Liu, Shuangyou

doi:10.1002/cyto.b.22060

Cited by 3 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(b) ELISA [34] is an enzyme immunoassay technique, which quantifies the binding of protein antigens to a solid‐phase carrier. (c) Flow cytometry [35] uses fluorochrome‐conjugated antibodies to determine the expression of specific proteins in tumor cells. (d) Immunohistochemistry (IHC) uses immunofluorescence to ascertain the spatial arrangement of proteins within sections of tumor tissue.…”

Section: Methods For Detecting Car‐t‐cell Efficacy Prediction Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods

Zou,

Song,

et al. 2024

iLABMED

View full text Add to dashboard Cite

Cancer immunotherapy has emerged as the fourth most prevalent approach to tumor treatment, alongside surgery, radiotherapy, and chemotherapy. After several decades of development, chimeric antigen receptor T (CAR‐T) cell therapy, a promising branch of adoptive T‐cell therapy, has demonstrated superior efficacy and safety in comparison to other cell therapies in the treatment of cancer. At present, CAR‐T cells are predominantly used to treat hematological malignancies, although their application in solid tumors is being readily investigated. Although numerous studies have examined the biomarkers associated with the safety of CAR‐T cell therapy, few have evaluated predictors of CAR‐T cell therapeutic efficacy. Thus, the primary objective of this review article was to provide a comprehensive overview of the factors predicting the efficacy of CAR‐T cell therapy, with a particular focus on biomarkers and their detection methods.

show abstract

Section: Methods For Detecting Car‐t‐cell Efficacy Prediction Biomarkersmentioning

confidence: 99%

“…Flow cytometry [28] CBA [29,30] Cell subtypes CD4þT ABC [31] CD8þT IGSS [31] Treg APAAP method [31] Immunofluorescence technology [31] Flow cytometry [32] Antigen density CD19 Western blots [33] CD22 ELISA [34] BCMA IHC Flow cytometry [35] T A B L E 1 (Continued)…”

Section: Tumor Burdenmentioning

confidence: 99%

Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods

Zou,

Song,

et al. 2024

iLABMED

View full text Add to dashboard Cite

show abstract

“…CAR‐T‐cell therapy has been recently approved in United States and Europe for the treatment of several hematological malignancies, since it achieved impressive results in patients with relapsed/refractory B‐acute lymphocytic leukemia (B‐ALL) and diffuse large B‐cell lymphoma (DLBCL) (Johansson et al, 2021; Lanza & Maffini, 2020; Maryamchik et al, 2020; Sarikonda et al, 2020; Yu et al, 2022). However, an increasing body of evidence suggests that a sizeable proportion of patients treated with CAR‐T cells do not experience a long‐term response.…”

mentioning

confidence: 99%

“…The submitting authors have hypothisized that the occurrence of BIA-ALCL in Brazil is underreported, and therefore it is important to focus on this subject to better investigate this disease. In this report, the authors concluded that the application of FC with a comprehensive antibody panel consisting of CD30 in conjunction with CD25 and HLA-DR can discriminate anaplastic cells of breast implantassociated anaplastic large cell lymphoma from lymphoid or neutrophilic reactive cells and should be considered in the initial evaluation of these lymphoma entities(De Azambuja et al, 2022;Debliquis et al, 2020;Wong-Arteta et al, 2020).CAR-T-cell therapy has been recently approved in United Statesand Europe for the treatment of several hematological malignancies, since it achieved impressive results in patients with relapsed/ refractory B-acute lymphocytic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL)(Johansson et al, 2021;Maryamchik et al, 2020;Sarikonda et al, 2020;Yu et al, 2022). However, an increasing body of evidence suggests that a sizeable proportion of patients treated with CAR-T cells do not experience a long-term response.…”

mentioning

confidence: 99%

Issue Highlights—July 2022

Lanza

Rondoni

2022

Cytometry Part B Clinical

View full text Add to dashboard Cite

2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization

Sumner,

Keller,

Huleatt

et al. 2023

Bioanalysis

View full text Add to dashboard Cite

The 16th Workshop on Recent Issues in Bioanalysis (16th WRIB) took place in Atlanta, GA, USA on September 26–30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 16th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week in order to allow exhaustive and thorough coverage of all major issues in bioanalysis, biomarkers, immunogenicity, gene therapy, cell therapy and vaccines. Moreover, in-depth workshops on ICH M10 BMV final guideline (focused on this guideline training, interpretation, adoption and transition); mass spectrometry innovation (focused on novel technologies, novel modalities, and novel challenges); and flow cytometry bioanalysis (rising of the 3rd most common/important technology in bioanalytical labs) were the special features of the 16th edition. As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues. This 2022 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2022 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 2) covers the recommendations on LBA, Biomarkers/CDx and Cytometry. Part 1 (Mass Spectrometry and ICH M10) and Part 3 (Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity) are published in volume 15 of Bioanalysis, issues 16 and 14 (2023), respectively.

show abstract

Quick identification of target antigens by tissue flow cytometry for CAR‐T therapy in B‐cell malignancies

Cited by 3 publications

References 2 publications

Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods

Biomarkers for predicting efficacy of chimeric antigen receptor T cell therapy and their detection methods

Issue Highlights—July 2022

Contact Info

Product

Resources

About